Home/Xeris Pharmaceuticals/R. Drew Nordlicht
RD

R. Drew Nordlicht

Chief Commercial Officer

Xeris Pharmaceuticals

Xeris Pharmaceuticals Pipeline

DrugIndicationPhase
Gvoke (glucagon)Severe HypoglycemiaApproved
Gvoke PFSPediatric Severe HypoglycemiaApproved
Keveyis (dichlorphenamide)Primary Periodic ParalysisApproved
Recorlev (levoketoconazole)Endogenous Cushing's SyndromeApproved
XP-8121 (Liquid Glucagon)Bi-hormonal Pump for DiabetesPhase 2
XP-8121Congenital HyperinsulinismPreclinical/Phase 1
OgluoSevere HypoglycemiaApproved